Items Tagged ‘Dr. Moses Rodriguez’

October 28th, 2017

Mayo Clinic in the News Weekly Highlights

By Karl W Oestreich KarlWOestreich

Mayo Clinic in the News is a weekly highlights summary of major media coverage. If you would like to be added to the weekly distribution list, send a note to Emily Blahnik with this subject line: SUBSCRIBE to Mayo Clinic in the News. Editor, Karl Oestreich;  Assistant Editor: Emily Blahnik   Reuters Heart health disparities take toll on African-Americans by Will Boggs Dr. […]

View full entry

Tags: ABC 15 Arizona, AccuWeather, Action News Jax, African-Americans, aging, AliveCor, alzheimer's disease, Amazon Alexa, amputees, Amsterdam News, anesthesia, ASU


September 28th, 2017

Mayo Clinic in the News Weekly Highlights

By Emily Blahnik eblahnik

Mayo Clinic in the News is a weekly highlights summary of major media coverage. If you would like to be added to the weekly distribution list, send a note to Emily Blahnik with this subject line: SUBSCRIBE to Mayo Clinic in the News. Editor, Karl Oestreich;  Assistant Editor: Emily Blahnik   Washington Post Letting a dog sleep on your bed does not actually […]

View full entry

Tags: Acorda Therapeutics, Addiction Now, Alzforum, alzheimer's disease, Amazon Alexa, Arizona Daily Sun, artificial Intelligence, Barron News-Shield, Becker’s Hospital Review, birth defects, Bloomington Pantagraph, brain cancer


April 24th, 2013

Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis

By Logan Lafferty loganlafferty

Mayo Clinic and Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS)… “This remyelinating antibody, if successful in clinical trials and approved, would be a novel approach to treating people with […]

View full entry

Tags: Acorda Therapeutics, antibody, chronic neurologic deficits, clinical trial, Dr. Moses Rodriguez, MS, multiple sclerosis, rHIgM22, Wall Street Journal


Contact Us · Privacy Policy